Fox Point Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Fox Point Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-25,000	Closed	-$1.56M	–	25
2015 Q1	$1.56M	Hold	25,000	–	–	1.02%	20
2014 Q4	$1.44M	Hold	25,000	–	–	0.86%	22
2014 Q3	$1.34M	Sell	25,000 -75,000	-75%	-$3.97M	1.23%	18
2014 Q2	$5.24M	Buy	100,000 +25,000	+33%	+$1.28M	3.97%	13
2014 Q1	$3.96M	Buy	+75,000	New	+$3.47M	3%	18

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Fox Point Capital Management's TEVA Position: Q2 2015 in Review

Fox Point Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 25,000 shares — an estimated $1.56M sold.

Fox Point Capital Management first reported a position in TEVA in Q1 2014 and held it in 5 quarters. The position peaked at $5.24M in Q2 2014. 818 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

Fox Point Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Fox Point Capital Management sold 25,000 Teva Pharmaceuticals shares in Q2 2015, an estimated $1.56M.
Fox Point Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 5 quarters.
Fox Point Capital Management's Teva Pharmaceuticals position peaked at $5.24M in Q2 2014.
818 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on Fox Point Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.